Application of CDCA8 in preparation of drug for treating ovarian cancer

A technology for ovarian cancer and ovarian cancer cells, applied in the field of biomedicine, can solve the problem of no research on the relationship between chemotherapy and drug resistance of ovarian cancer, and achieve the effect of inhibiting cell apoptosis
CN112007161AActive Publication Date: 2020-12-01SHANDONG UNIV QILU HOSPITAL
4 Cites 5 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
SHANDONG UNIV QILU HOSPITAL
Publication Date
2020-12-01

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the field of biological medicines, and particularly relates to an application of CDCA8 in the preparation of a drug for treating ovarian cancer. The invention provides an application of a reagent for inhibiting CDCA8 gene expression or inhibiting a CDCA8 gene expression product in the preparation of a drug for treating ovarian cancer and / or inhibiting proliferation, invasion and migration of ovarian cancer cells and at the same time promoting ovarian cancer cell cycle arrest and apoptosis. In addition, the inhibition of the expression of CDCA8 or the inhibition of theCDCA8 gene expression product can enhance the sensitivity of ovarian cancer cells to chemotherapeutic drugs cisplatin and olaparib by adjusting the cell cycle and inhibiting DNA damage repair. A new thought is provided for screening drugs for treating ovarian cancer, especially serous ovarian cancer, and a new method is provided for enhancing the sensitivity to traditional ovarian cancer chemotherapeutic drugs.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of biomedicine, in particular to the application of CDCA8 in the preparation of drugs for treating ovarian cancer. Background technique

[0002] The information disclosed in this background section is only intended to increase the understanding of the general background of the present invention, and is not necessarily taken as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to those skilled in the art.

[0003] Ovarian cancer is one of the most common gynecological malignancies, and its mortality rate ranks first among gynecological malignancies. Serous ovarian carcinoma (SOC) is the most common epithelial ovarian cancer, with high malignancy and poor prognosis.

[0004] At present, the first-line treatment for ovarian cancer is still cytoreductive surgery and platinum / paclitaxel-based chemotherapy, but most patients will relapse and drug resistance. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More